ioGenetics
ioGenetics specializes in designing and producing recombinant proteins, including vaccines and therapeutics, with a focus on proprietary antimicrobial proteins. They utilize advanced platform technologies and have an extensive intellectual property portfolio, including novel antibodies and antibody fusion products, primarily targeting antimicrobial and antiviral applications.
Industries
Nr. of Employees
small (1-50)
ioGenetics
Madison, Wisconsin, United States, North America
Patents
Modified Zika virus NS1 protein with reduced cross-reactive immunogenicity
US-11434259-B2
View DetailsIdentifying peptides having T-cell-exposed motifs with known frequency of occurrence in a reference database
US-10755801-B2
View Details
Modified Zika virus NS1 protein with reduced cross-reactive immunogenicity
US-11434259-B2
View DetailsIdentifying peptides having T-cell-exposed motifs with known frequency of occurrence in a reference database
US-10755801-B2
View DetailsProducts
Recombinant antimicrobial protein candidates
Recombinant proteins developed as antimicrobial agents targeting protozoan, bacterial, and viral pathogens.
Antibodies and antibody-fusion proteins
Engineered monoclonal antibodies and antibody-fusion constructs produced using retrovector-mediated mammalian expression systems.
Vaccine and therapeutic protein candidates
Protein-based vaccine antigens and therapeutic protein candidates derived from the company's recombinant protein platform.
Recombinant antimicrobial protein candidates
Recombinant proteins developed as antimicrobial agents targeting protozoan, bacterial, and viral pathogens.
Antibodies and antibody-fusion proteins
Engineered monoclonal antibodies and antibody-fusion constructs produced using retrovector-mediated mammalian expression systems.
Vaccine and therapeutic protein candidates
Protein-based vaccine antigens and therapeutic protein candidates derived from the company's recombinant protein platform.
Services
Support for licensing of protein products and platform technologies and engagement with external partners for development opportunities.
Support for licensing of protein products and platform technologies and engagement with external partners for development opportunities.
Expertise Areas
- Recombinant protein production
- Antimicrobial therapeutic development
- Antibody engineering and fusion proteins
- Vaccine antigen and protein therapeutic development
Key Technologies
- Recombinant protein expression
- Mammalian cell expression systems
- Retroviral/retrovector-based delivery platforms
- Antibody engineering